LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway

doi:10.3748/wjg.v17.i2.181

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5438)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

408

HTML

4793

Figures (1-5)

237

Sum=5438

Jan 14, 2011 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Jan 14, 2011; 17(2): 181-190
Published online Jan 14, 2011. doi: 10.3748/wjg.v17.i2.181

Full Size Figure Download Figure

Figure 4 Fas ligand siRNA attenuated oxaliplatin-, LY294002-, or combination-induced cell apoptosis. A: Fas ligand (FasL) expression was inhibited by FasL siRNA in MKN45 and AGS cells; B: FasL silencing decreased oxaliplatin-, LY294002-, or combination-induced cell apoptosis. ^aP < 0.05 vs LY294002 treatment; ^bP < 0.01 vs oxaliplatin treatment; ^dP < 0.01 vs combination of oxaliplatin and LY294002.

Citation: Liu J, Fu XQ, Zhou W, Yu HG, Yu JP, Luo HS. LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway. World J Gastroenterol 2011; 17(2): 181-190
URL: https://www.wjgnet.com/1007-9327/full/v17/i2/181.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i2.181